ALT-946 and Aminoguanidine, Inhibitors of Advanced Glycation, Improve Severe Nephropathy in the Diabetic Transgenic (mREN-2)27 Rat
Open Access
- 1 November 2002
- journal article
- Published by American Diabetes Association in Diabetes
- Vol. 51 (11) , 3283-3289
- https://doi.org/10.2337/diabetes.51.11.3283
Abstract
The severe diabetic nephropathy that develops in the hypertensive transgenic (mRen-2)27 rat with streptozotocin (STZ) diabetes has previously been considered anKeywords
This publication has 37 references indexed in Scilit:
- Interaction of metabolic and haemodynamic factors in mediating experimental diabetic nephropathyDiabetologia, 2001
- Renoprotective effects of a novel inhibitor of advanced glycationDiabetologia, 2001
- Advanced glycation end products induce apoptosis and procoagulant activity in cultured human umbilical vein endothelial cellsDiabetes Research and Clinical Practice, 1999
- Suppression of transforming growth factor beta and vascular endothelial growth factor in diabetic nephropathy in rats by a novel advanced glycation end product inhibitor, OPB-9195Diabetologia, 1999
- A novel inhibitor of advanced glycation end-product formation inhibits mesenteric vascular hypertrophy in experimental diabetesDiabetologia, 1999
- Advanced glycation end products and their receptors co-localise in rat organs susceptible to diabetic microvascular injuryDiabetologia, 1997
- Effects of aminoguanidine on serum advanced glycation endproducts, urinary albilmin excretion, mesangial expansion, and glomerular basement membrane thickening in Otsuka Long-Evans Tokushima fatty ratsDiabetes Research and Clinical Practice, 1997
- Aminoguanidine inhibits the development of accelerated diabetic retinopathy in the spontaneous hypertensive ratDiabetologia, 1994
- The Extracellular Matrix in Diabetic NephropathyAmerican Journal of Kidney Diseases, 1993
- The enhancement of aminonucleoside nephrosis by the co-administration of protamineKidney International, 1987